Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases

Kim, Eujin; Jang, Eungyeong; Lee, Jang-Hoon

doi:10.3390/nu14040867

Cited by 20 publications

(12 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diosgenin is abundant in yam, Study confirmed that the abundant diosgenin in yam could suppress excessive weight gain, reduce serum levels of total cholesterol and triglycerides, and decrease liver fat accumulation in high-fat diet-induced NAFLD rats ( Zhou Y et al, 2022 ). Hawthorn could reduce blood lipid, especially serum TG level ( Al Humayed, 2016 ; Han et al, 2016 ; Kim et al, 2022 ). Curcumin in turmeric could reduce blood lipid ( Jarhahzadeh et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis

Zhang

Liu²,

Gu³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The incidence of Non-alcoholic fatty liver disease (NAFLD) is increasing year by year. Researches showed that Chinese patent medicines (CPMs) had achieved good efficacy in the treatment of Non-alcoholic fatty liver disease. However, the debate on optimum Chinese patent medicine (CPM) persists. Therefore, we conducted a network meta-analysis to objectively compare the efficacy of different Chinese patent medicines in the treatment of Non-alcoholic fatty liver disease.Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Database, China Science and Technology Journal Database, and Chinese Biomedical Literature Database were used as databases for RCT researches retrieval. The retrieval time was from establishment of the database to July 2022. After effective data was extracted, Review Manager 5.4 and Cochrane Collaboration System Evaluator’s Manual were used to assess bias risk. STATA 16.0 based on frequency theory was used for the network meta-analysis.Results: Totally 39 studies were included, involving 13 Chinese patent medicines, including 4049 patients, of which 42 patients were lost. In terms of improving clinical efficiency rate, Zhibitai capsule was most likely the best choice of Chinese patent medicine for Non-alcoholic fatty liver disease. Liuwei Wuling tablet had the best effect in reducing serum ALT and AST; Gandan Shukang capsule had the best effect in reducing serum GGT; Qianggan capsule had the best effect in reducing serum TG; Dangfei Liganning capsule had the best effect in reducing serum TC. None of the included studies had serious adverse reactions.Conclusion: For patients with Non-alcoholic fatty liver disease in this NMA, Zhibitai capsule, Liuwei Wuling tablet, Gandan Shukang capsule, Qianggan capsule, Dangfei Liganning capsule might be noteworthy. Due to the uclear risk bias, better designed double-blind, multi center and large sample RCTs are needed which resolve the problems of blinding, selective reporting and allocation concealment.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier CRD42022341240.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis

Zhang

Liu²,

Gu³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…In recent years, the AMPK signaling pathway has been shown to be associated with the alleviation of metabolic disorders in many studies on the treatment of NAFLD. Activation of AMPK signaling pathway is a common feature of NAFLD treatment ( Chen et al, 2019 ; Zhou et al, 2021 ; Chen et al, 2022 ; Kim et al, 2022 ; Liao et al, 2022 ; Zhang and Feng, 2022 ). Activated AMPK signaling pathway in the liver reduces NAFLD mainly by reducing lipid production in the liver and regulating fatty acid oxidation in the liver ( Day et al, 2017 ; von Loeffelholz et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet

Meng

Huo

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and is a nutritional metabolic disease. Artemisia capillaris (AC) is the above-ground dried part of Artemisia capillaris Thunb. or Artemisia scoparia Waldst. et Kit., a natural medicinal plant with pharmacological effects of heat-clearing and biliary-promoting. In order to evaluate the therapeutic effect of Artemisia capillaris on NAFLD and obesity, experiments were conducted using aqueous extracts of Artemisia capillaris (WAC) to intervene in NAFLD models in vivo and in vitro. In vivo experiments were performed using HFD-fed (high fat diet) C57BL/6 mice to induce NAFLD model, and in vitro experiments were performed using oleic acid to induce HepG2 cells to construct NAFLD cell model. H.E. staining and oil red O staining of liver tissue were used to observe hepatocytes. Blood biochemistry analyzer was used to detect serum lipid levels in mice. The drug targets and mechanism of action of AC to improve NAFLD were investigated by western blotting, qRT-PCR and immunofluorescence. The results showed that C57BL/6 mice fed HFD continuously for 16 weeks met the criteria for NAFLD in terms of lipid index and hepatocyte fat accumulation. WAC was able to reverse the elevation of serum lipid levels induced by high-fat diet in mice. WAC promoted the phosphorylation levels of PI3K/AKT and AMPK in liver and HepG2 cells of NAFLD mice, inhibited SREBP-1c expression, reduced TG and lipogenesis, and decreased lipid accumulation. In summary, WAC extract activates PI3K/AKT pathway, reduces SREBP-1c protein expression by promoting AMPK phosphorylation, and decreases fatty acid synthesis and TG content in hepatocytes. AC can be used as a potential health herb to improve NAFLD and obesity.

show abstract

“… 2013 ; Kim et al. 2022 ;). As a medicinal and edible plant, there are few reports on the research of C. scabrifolia at present, which only reported its chemical constituents (Dahmer and Scott 2010 ).…”

Section: Introductionmentioning

confidence: 99%

The complete chloroplast genome of Crataegus scabrifolia (Franch.) Rehd (Rosaceae), a medicinal and edible plant in Southwest China

Tian

Zhao

2023

Mitochondrial DNA Part B

View full text Add to dashboard Cite

Crataegus scabrifolia (Franch.) Rehd is a medicinal and edible plant in Southwest China. The chloroplast genome of C. scabrifolia was analyzed by high-throughput sequencing technology, and its genetic relationship to related species was discussed. The chloroplast genome is 159,637 bp long, with two inverted repeat (IR) regions (26,384 bp each) that separate a large single-copy (LSC) region (87,730 bp) and a small single-copy (SSC) region (19,139 bp). A total of 127 genes were annotated, including 83 protein-coding genes, 8 rRNA genes, and 36 tRNA genes. The phylogenetic tree shows that C. hupehensis is closely related to C. scabrifolia with strong bootstrap support.

show abstract

Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases

Cited by 20 publications

References 84 publications

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis

Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet

The complete chloroplast genome of Crataegus scabrifolia (Franch.) Rehd (Rosaceae), a medicinal and edible plant in Southwest China

Contact Info

Product

Resources

About